Sotio, a clinical stage immuno-oncology company owned by PPF Group,  has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.   Sotio will build on Unum’s R&D data, its team and a portion of its laboratory and manufacturing facility to creat...